Latest From MakScientific LLC
Glaxo sold a European portfolio of non-core OTC products to Omega Pharma for $614 million. Device companies Zoll Medical and Cameron Health were acquired in two separate billion-dollar-plus deals. Biopharma funding reached $1 billion and device firms raised $539 million.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Shire addresses its Replagal disappointment with the acquisition of FerroKin and its hematology pipeline.
- Therapeutic Areas
- Metabolic Disorders
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- MakScientific LLC
- Senior Management
- Henry H Penner, CEO
- Contact Info
P.O. Box 188 Watertown, MA 02471
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.